These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 35806118)
1. Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy. Wang X; Lu X; Yan D; Zhou Y; Tan X Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806118 [TBL] [Abstract][Full Text] [Related]
2. AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model. Goswami A; Deb B; Goyal S; Gosavi A; Mali M; Martis AM; Khurana P; Gangar M; Raykar D; Mohanty A; Kulkarni A Molecules; 2022 Oct; 27(19):. PubMed ID: 36235254 [TBL] [Abstract][Full Text] [Related]
3. Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects. Guan D; Fang L; Feng M; Guo S; Xie L; Chen C; Sun X; Wu Q; Yuan X; Xie Z; Zhou J; Zhang H Eur J Med Chem; 2024 Mar; 267():116211. PubMed ID: 38359537 [TBL] [Abstract][Full Text] [Related]
4. Discovery of Pyrido[2,3- Sun Y; Chen M; Han Y; Li W; Ma X; Shi Z; Zhou Y; Xu L; Yu L; Wang Y; Yu J; Diao X; Meng L; Xu S J Med Chem; 2024 Mar; 67(5):3986-4006. PubMed ID: 38387074 [TBL] [Abstract][Full Text] [Related]
5. Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling. An Y; Zhu J; Xie Q; Feng J; Gong Y; Fan Q; Cao J; Huang Z; Shi W; Lin Q; Wu L; Yang C; Ji T Adv Sci (Weinh); 2024 May; 11(20):e2308131. PubMed ID: 38498770 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy. Cho Y; Kang M; Ji SH; Jeong HJ; Jung JE; Oh DH; Park S; Park YY; Choi J; Kim S; Kim NJ; Lee DH; Park CS; Han SJ; Lee S; Choi J J Med Chem; 2023 Nov; 66(22):15141-15170. PubMed ID: 37963811 [TBL] [Abstract][Full Text] [Related]
7. ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer. Wang S; Böhnert V; Joseph AJ; Sudaryo V; Skariah G; Swinderman JT; Yu FB; Subramanyam V; Wolf DM; Lyu X; Gilbert LA; Van't Veer LJ; Goodarzi H; Li L Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2313693120. PubMed ID: 38117852 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy. Gangar M; Goyal S; Raykar D; Khurana P; Martis AM; Goswami A; Ghoshal I; Patel KV; Nagare Y; Raikar S; Mukherjee A; Cyriac R; Paquin JF; Kulkarni A Bioorg Chem; 2022 Feb; 119():105549. PubMed ID: 34929517 [TBL] [Abstract][Full Text] [Related]
9. ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1. Onyedibe KI; Wang M; Sintim HO Molecules; 2019 Nov; 24(22):. PubMed ID: 31752288 [TBL] [Abstract][Full Text] [Related]
10. Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP. Carozza JA; Brown JA; Böhnert V; Fernandez D; AlSaif Y; Mardjuki RE; Smith M; Li L Cell Chem Biol; 2020 Nov; 27(11):1347-1358.e5. PubMed ID: 32726585 [TBL] [Abstract][Full Text] [Related]
12. Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors. Jeong HJ; Lee HL; Kim SJ; Jeong JH; Ji SH; Kim HB; Kang M; Chung HW; Park CS; Choo H; Yoon HJ; Kim NJ; Lee DH; Lee SH; Han SJ J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2434-2451. PubMed ID: 36069240 [TBL] [Abstract][Full Text] [Related]
13. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway. Ding C; Song Z; Shen A; Chen T; Zhang A Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501 [TBL] [Abstract][Full Text] [Related]
14. Identification of the extracellular membrane protein ENPP3 as a major cGAMP hydrolase and innate immune checkpoint. Mardjuki R; Wang S; Carozza J; Zirak B; Subramanyam V; Abhiraman G; Lyu X; Goodarzi H; Li L Cell Rep; 2024 May; 43(5):114209. PubMed ID: 38749434 [TBL] [Abstract][Full Text] [Related]
15. Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors. Jung JE; Jang Y; Jeong HJ; Kim SJ; Park K; Oh DH; Yu A; Park CS; Han SJ Bioorg Med Chem Lett; 2022 Nov; 75():128947. PubMed ID: 35995398 [TBL] [Abstract][Full Text] [Related]
16. ENPP1's regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling. Carozza JA; Cordova AF; Brown JA; AlSaif Y; Böhnert V; Cao X; Mardjuki RE; Skariah G; Fernandez D; Li L Proc Natl Acad Sci U S A; 2022 May; 119(21):e2119189119. PubMed ID: 35588451 [TBL] [Abstract][Full Text] [Related]
17. Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone. Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S Biochem Pharmacol; 2024 Feb; 220():116006. PubMed ID: 38142838 [TBL] [Abstract][Full Text] [Related]
18. [1,2,4]Triazolo[1,5-a]pyrimidine derivatives: Structure-activity relationship study leading to highly selective ENPP1 inhibitors. Kawaguchi M; Minami S; Ieda N; Nakagawa H Bioorg Med Chem Lett; 2024 Sep; 110():129820. PubMed ID: 38851358 [TBL] [Abstract][Full Text] [Related]
19. Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Li L; Yin Q; Kuss P; Maliga Z; Millán JL; Wu H; Mitchison TJ Nat Chem Biol; 2014 Dec; 10(12):1043-8. PubMed ID: 25344812 [TBL] [Abstract][Full Text] [Related]
20. The cyclic guanosine monophosphate synthase-stimulator of interferon genes pathway as a potential target for tumor immunotherapy. Chen R; Liu M; Jiang Q; Meng X; Wei J Front Immunol; 2023; 14():1121603. PubMed ID: 37153627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]